Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension.

Protamine is used after cardiopulmonary bypass was stopped in order to reverse the anticoagulant effects of heparin administered during open-heart operations. Adverse hemodynamic responses to protamine are common, ranging from minor perturbations to cardiovascular collapse. The aim of the present study was to investigate whether a prostacyclin is effective in the treatment of protamine-mediated acute pulmonary hypertension and right ventricular failure in the perioperative period of isolated coronary artery bypass grafting (CABG) operations. In sixty-eight (1.78%) of 3800 patients who underwent isolated CABG, acute pulmonary hypertension and right ventricular failure developed during or following the protamine infusion. These 68 patients were included in the study and were randomized into two groups. Thirty-eight of the patients received prostaglandin I(2) (PGI(2)), norepinephrine and dopamine (PGI(2) group), whereas 30 patients received nitroglycerin, norepinephrine and dopamine (control group). Hemodynamic data were recorded before and after the above drug combinations. The mean value of left ventricle ejection fraction significantly increased (p < 0.05) and mean values of central venous pressure, pulmonary artery systolic and diastolic pressure, pulmonary capillary wedge pressure and pulmonary vascular resistance significantly decreased (p < 0.05) in the PGI(2) group. The mean value of pulmonary capillary wedge pressure significantly decreased (p < 0.05) and the mean value of central venous pressure significantly increased (p < 0.05) in the control group. In conclusion, prostacyclin (PGI(2)) is effective in the treatment of protamine-mediated acute pulmonary hypertension and right ventricular failure in the perioperative period in isolated CABG operations. This finding may be an important contribution to the treatment of severe protamine complications during open-heart operations.

[1]  O. Goksel,et al.  Carotid-subclavian bypass in occlusive disease of subclavian artery: more important today than before. , 2004, The Tohoku journal of experimental medicine.

[2]  G. Dehmer,et al.  Recombinant platelet factor 4 for heparin neutralization. , 2004, Seminars in thrombosis and hemostasis.

[3]  P. Evora,et al.  Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated: should methylene blue be the treatment of choice? , 2002, Chest.

[4]  G. Gravlee,et al.  A Dose-Determining Trial of Heparinase-I (Neutralase™) for Heparin Neutralization in Coronary Artery Surgery , 2001, Anesthesia and analgesia.

[5]  M. Kikura,et al.  Heparinase I (Neutralase) Reversal of Systemic Anticoagulation , 1996, Anesthesiology.

[6]  H. Schaff,et al.  Protamine induces endothelium-dependent vasodilatation of the pulmonary artery. , 1995, The Annals of thoracic surgery.

[7]  J. Levy,et al.  Heparin Neutralization by Recombinant Platelet Factor 4 and Protamine , 1995, Anesthesia and analgesia.

[8]  M. Fisher,et al.  Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. , 1995, Circulation.

[9]  L. Edmunds,et al.  Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass. , 1995, The Journal of thoracic and cardiovascular surgery.

[10]  S. W. Kim,et al.  Heparin removal from blood using poly(L‐lysine) immobilized hollow fiber , 1992, Biotechnology and bioengineering.

[11]  H. Schaff,et al.  Protamine Releases Endothelium‐Derived Relaxing Factor From Systemic Arteries: A Possible Mechanism of Hypotension During Heparin Neutralization , 1992, Circulation.

[12]  D. Mosser,et al.  Platelet Factor 4 Efficiently Reverses Heparin Anticoagulation in the Rat Without Adverse Effects of Heparin–Protamine Complexes , 1992, Circulation.

[13]  J. Wain,et al.  Inhaled nitric oxide. A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. , 1991, Anesthesiology.

[14]  K. Peter,et al.  [Complications caused by protamine. 1: Pharmacology and pathophysiology]. , 1991, Der Anaesthesist.

[15]  W. Weintraub,et al.  Evaluation of patients at risk for protamine reactions. , 1989, The Journal of thoracic and cardiovascular surgery.

[16]  S. Thomas,et al.  C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. , 1987, Anesthesiology.

[17]  T. Quattrociocchi-Longe,et al.  Interrelationship of protamine and platelet factor 4 in the neutralization of heparin. , 1987, Thrombosis research.

[18]  J. Zaidan,et al.  Prospective Evaluation of Risk of Protamine Reactions in Patients with NPH Insulin‐Dependent Diabetes , 1986, Anesthesia and analgesia.

[19]  T. Ryan,et al.  Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization. , 1984, Circulation.

[20]  B. Milne,et al.  The haemodynamic effects of intraaortic versus intravenous administration of protamine for reversal of heparin in man , 1983, Canadian Anaesthetists' Society journal.

[21]  H. Schaff,et al.  Cardiovascular effects of protamine sulfate in man. , 1982, The Journal of thoracic and cardiovascular surgery.

[22]  R. Frater,et al.  CARDIOVASCULAR EFFECTS OF RIGHT ATRIAL INJECTION OF PROTAMINE SULFATE AS COMPARED TO LEFT ATRIAL INJECTION , 1982 .

[23]  M. K. Sykes,et al.  Effects of heparin and protamine on left ventricular performance in the dog. , 1979, Cardiovascular research.